Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EPFL launches Protein Expression Core Facility

28.07.2006
EPFL is adding an exciting new dimension to the life science research capabilities in the Lake Geneva area and around Switzerland with the launching of a Protein Expression Core Facility. This facility, founded and directed by Professor Florian Wurm and located in EPFL’s Laboratory of Cellular Biotechnology, will provide recombinant proteins efficiently and at minimal cost to scientists doing basic research both within and outside Switzerland.

Producing proteins is a time-consuming, painstaking process, particularly from mammalian cell lines, and the investment required in terms of time, expertise, cost and infrastructure prevents most researchers from taking on the task in their own laboratories. Obtaining proteins from commercial sources is prohibitively expensive for scientists on tight budgets.

“Having this service close at hand has been fantastic for my research,” says EPFL researcher Patrick Fraering. “In my field [neurodegenerative disease] developments move very quickly. In order to stay competitive internationally, I need quick access to proteins from mammalian cell lines, and there is no way I could produce them with this level of efficiency myself.”

Building on the demonstrated benefits of the facility to EPFL researchers, the School of Life Sciences decided to formalize the facility and extend the service to scientists doing basic research outside EPFL. This will allow the Facility to recoup some costs and has the added benefit of stimulating collaborations and cross-institutional exchange. It’s cost-effective for users, because even though they will be charged a fee for the proteins, it’s far below what they would pay for commercial proteins and roughly a quarter of what it would cost them to produce the proteins themselves. And with a tight turnaround time – the facility can produce proteins from mammalian cells in less than four weeks – researchers can quickly follow up on promising leads. Once the development of a protein reaches a clinical or commercial stage, production will be transferred to a commercial facility.

The facility also provides training in gene transfer techniques and cultivation of cells in suspension. As facility manager David Hacker points out, “by offering guidance and training, we can enhance the chance that researchers’ projects will succeed.”

Recombinant proteins - From a Swiss past to a Swiss future?

In 1978, Swiss scientist Werner Arber shared the Nobel prize in medicine with Americans Daniel Nathans and Hamilton Smith for discovering a technique to incorporate non-native DNA into living cells. The re-combined, or “recombinant”, DNA holds instructions for the cell to produce the non-native protein which can subsequently be extracted and purified.

The 25,000 genes that make up human genome hold the blueprints for the manufacture of anywhere from 250,000 - 1 million proteins. But only about 50 of these proteins are understood well enough to be used in therapeutic applications. Insulin, EPO, and herceptin, an antibody used in breast cancer treatment, are a few better-known examples.

The global market for antibodies, proteins, and hormones produced using the recombinant DNA technique is currently on the order of $20 billion. Global demand for insulin is expected to rise by 14% annually. Most biomedical researchers agree that the therapeutic and market potential of recombinant proteins is not even close to being fully exploited. “It’s very important that we take advantage of the opportunities available in recombinant proteins,” notes Wurm. “A lack of opportunity for exploring this potential will diminish the European contribution to biomedical research considerably, and we’re likely to get left behind in the market as well.”

“If we want to jump-start biomedical research on proteins in Europe, the path from idea to innovation needs to be optimized,” urges Wurm. “With this facility, EPFL is in a key position to help make this happen.”

Mary Parlange | alfa
Further information:
http://actualites.epfl.ch/presseinfo-com?id=370

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>